Osteoarthritis is among the most prevalent degenerative joint diseases, affecting millions worldwide. Most treatments to date have targeted pain and inflammatory symptoms, while treatments for the future aim at slowing down, halting, and even reversing disease progressions. Many of these new treatments, starting soon, involve the use of stem cells which can regenerate damaged cartilage and reduce inflammation. Currently, it is being investigated whether stem cells derived from either the bone marrow or fat tissue or umbilical cord are able to improve cartilage repair and reduce symptoms of OA. Clinical trials that examine long-term efficacy and safety are ongoing. Platelet-rich plasma (PRP) is prepared by concentrating platelets taken from the patient's blood and then injecting such platelets into the joint. This type of therapy may stimulate processes of cartilage repair and reduction of inflammation. It currently has very limited application in OA, and more research is ongoing on optimizing its application as well as its long-term effects.

Another prospect is gene therapy that seeks to alter the genetic material of a patient so as to encourage the production of proteins that either protect cartilage or reduce inflammation. Research continues to identify the genes that could be targeted with a view to slowing down or halting the progress of OA. Certain new DMOADs have promise in the treatment of osteoarthritis-affected diseases. Development of DMOADs is designed not just simply to manage symptoms but actually to modify the disease process. They will hopefully protect cartilage, reduce degradation, and even begin regeneration of damaged tissues in the joint. A few of the promising candidates include Tanezumab, a monoclonal antibody that blocks the nerve growth factor, which is involved in pain signaling. This is presently being assessed as a new therapeutic approach in pain relief in OA, quite independent of NSAIDs. Other agents under study are matrix metalloproteinase inhibitors. MMPs are enzymes involved in collagen and cartilage degradation. The inhibition of these enzymes can presumably retard the breakdown of cartilage in OA. Another promising DMOAD is SM04690, also known as Lorecivivint, which has proven to have anti-inflammatory effects as well as the prevention of cartilage breakdown and stimulation of cartilage growth in clinical trials by being a small-molecule pathway inhibitor. This class includes monoclonal antibodies or proteins; biologics attack pathways that take part in the progression of OA. Examples include inhibitors of IL-1 and TNF-alpha. Cytokines are mediators of inflammation, and their inhibition could reduce inflammation in the joint and damage to cartilage. Like tanezumab, fasimumab also acts via NGF, lowering pain levels without affecting opioid receptors.

3D bioprinting and cartilage engineering use 3D printers to create personalized cartilage implants from a patient's cells or biomaterials. The investigators are working on inserts which can replace the damaged cartilage in the joints of OA patients and restore their function. Hydrogels and scaffolds support cartilage regeneration. Hydrogels are injected into the joint, where they solidify to provide a scaffold for the ingrowth of new cartilage cells. Such materials, when combined with growth factors or stem cells, may stimulate healing. Nanoparticles can also be designed to deliver drugs or growth factors to the joint in a much more effective and targeted way, thereby minimizing side effects and being more efficient in the treatment of OA. Current studies are testing the use of nanoparticles in the repair of cartilage and the delivery of drugs in OA. Next will come the senolytic medications that selectively target and clear the accumulation of senescent cells in OA joints known to drive inflammation and tissue degeneration. Senolytics, by eliminating these "aging" cells, may offer a way to slow or even reverse the course of OA.

On the surgical front, the development of robotic and arthroscopic techniques will further enhance the precision and success of joint replacement surgery for osteoarthritis. It minimizes the recovery time and makes the implants last longer. Imaging and manufacturing can provide joint replacements that are tailored to the anatomy of an individual. Such personalized implants may enhance joint function and decrease the possibility of complications.

There is an increasing number of observations that suggest a possible role for gut microbiota in modulating joint health and inflammatory states. Probiotics or nutritional strategies that improve gut health may decrease systemic inflammation and thus slow the progression of OA. Despite the long life of osteoarthritis, the outlook of osteoarthritis treatment is brilliant, as many therapies are shifting beyond symptom management to disease modification, tissue regeneration, and personalized medicine. These innovations may provide a complete revolution in treating OA and offer much more efficient and long-lasting remedies to the patients. Though some of the treatments are still in their infancy, others are already in clinical trials and may be available soon.